Troph Bio Company Profile, Contacts & Intelligence

Troph Bio Overview

The last decade of biopharmaceutial research has brought immense advancement leading to several biologics approved for the treatment of various human disease. There are about 30 approved biosimilars in the market and more are expected in the coming years. By the end of 2020, 12 biologics patents are set to expire and this trend is likely to continue in the coming years. The requirement of approval of biosimilar is that is is has to demonstrated that the biosimilar and reference compound are similar by analytical and clinical characterization methods. Bioprocessing of biosimilars could results in impurities that may have to be characterized especially for immunogenecity. Early assessment of immuonogenecity is highly desirable in understanding the complexity of downstream processing. Modern technologies allows us to determine the possible T -Cell immune response that helps in better manuovering of procees development. We can help in conducting specific immunogenicity analysis that will help you make data driven decision for your program Start Bootstrap has everything you need to get your new website up and running in no time! Choose one of our open source, free to download, and easy to use themes! No strings attached!

Headquarters

Chennai, Tamil Nadu, In

Website

www.trophbio.com

Industry

Biotechnology Research

Founded

2017

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Compare Similar Companies to Troph Bio

Explore companies in related markets and compare their industry and employee estimates.